Emerging pharmaceutical companies face increasing pressure to scale quickly while managing lean teams, limited resources, and rising expectations for agent AI. On this episode of The Top Line, Fierce Biotech host Kelly Hogan is joined by JR Raelin, executive director of analytics and insights at SynOx Therapeutics, and Krishna GS, business technology solutions manager at ZS, to discuss why execution, not insight, is often the biggest challenge.
Raelin and Krishna outline common technology roadmap mistakes for young and emerging organizations, including pursuing new technologies and AI without a strong data foundation, allowing the proliferation of siled point solutions, and under-investing in integration and interoperability. They are implementing a three-horizon agent maturity framework, from building a governed data foundation pre-launch, through deploying execution agents that drive targeting, field coordination, and omnichannel engagement, to establishing portfolio-level intelligence that turns learnings from the first launch into a competitive advantage for all subsequent products.
Rather than treating AI as a destination, this discussion positions agent AI as an operating model that connects data, decisions, and workflows into a single, trusted system. Drawing on their experience across biopharma and life sciences, speakers will share practical guidance on sequencing investments, incorporating human oversight and explainability, and connecting workflows across commercial, medical, and patient teams to translate AI-driven insights into real-world business decisions.
This conversation explores common pitfalls, including following new technology and AI trends before establishing data readiness, underinvesting in integration, and relying on fragmented point solutions. Raelin and Krishna explain why a strong data foundation, governance, and interoperability are prerequisites, and how agent AI, when built on that foundation, can bridge the gap between insight and action in real-world commercial workflows.
Listeners will also hear a framework for scaling the platform over time, guidance on how to effectively implement the first 60-90 days, and examples of connected workflows across commercial, medical, and patient functions. This episode ends with a compelling case for why an agent roadmap is the most important strategic asset a first-launching company builds before a second product, and how doing it right can turn a single launch into a portfolio intelligence engine.
